ADNAS Terminates Material Definitive Agreement, Effective Jan 30
Ticker: BNBX · Form: 8-K · Filed: Jan 31, 2024 · CIK: 744452
Complexity: simple
Sentiment: neutral
Topics: agreement-termination, corporate-action, 8-K
TL;DR
**ADNAS just terminated a key agreement, watch for potential business impact.**
AI Summary
Applied DNA Sciences, Inc. (ADNAS) filed an 8-K on January 31, 2024, to report the termination of a material definitive agreement, effective January 30, 2024. This termination could impact ADNAS's future revenue streams or operational strategies, as material agreements often relate to significant partnerships, supply contracts, or licensing deals. Investors should understand that the termination of such an agreement might signal a shift in the company's business focus or a potential loss of expected income, which could affect the stock's valuation.
Why It Matters
The termination of a material definitive agreement can signal a change in business strategy, a loss of a significant revenue source, or the end of a key partnership, all of which could impact the company's financial performance and stock price.
Risk Assessment
Risk Level: medium — The filing indicates the termination of a 'material definitive agreement' without specifying details, which introduces uncertainty about its impact on the company's operations and financials.
Analyst Insight
A smart investor would seek further clarification from Applied DNA Sciences, Inc. regarding the specific agreement terminated and its financial implications, as this filing lacks crucial details to assess the impact.
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — the registrant filing the 8-K
- January 30, 2024 (date) — date of the earliest event reported and effective date of termination
- January 31, 2024 (date) — date the 8-K was filed
- 50 Health Sciences Drive, Stony Brook, New York 11790 (address) — principal executive offices of Applied DNA Sciences, Inc.
- 631-240-8800 (phone_number) — registrant's telephone number
FAQ
What is the specific item number under which Applied DNA Sciences, Inc. reported this event?
Applied DNA Sciences, Inc. reported this event under Item 1.02, 'Termination of a Material Definitive Agreement,' as indicated in the filing's 'ITEM INFORMATION' section.
What is the exact date the event reported in this 8-K filing occurred?
The earliest event reported, which is the termination of the material definitive agreement, occurred on January 30, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
What is the business address of Applied DNA Sciences, Inc. as listed in the filing?
The business address of Applied DNA Sciences, Inc. is 50 Health Sciences Drive, Stony Brook, New York 11790, as detailed in the 'BUSINESS ADDRESS' section of the filing.
What is the Commission File Number for Applied DNA Sciences, Inc.?
The Commission File Number for Applied DNA Sciences, Inc. is 001-36745, as specified in the filing.
What is the Central Index Key (CIK) for Applied DNA Sciences, Inc.?
The Central Index Key (CIK) for Applied DNA Sciences, Inc. is 0000744452, as listed under 'FILER: COMPANY DATA'.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-01-30 21:21:35
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- tm244443d1_8k.htm (8-K) — 23KB
- 0001104659-24-008438.txt ( ) — 189KB
- apdn-20240130.xsd (EX-101.SCH) — 3KB
- apdn-20240130_lab.xml (EX-101.LAB) — 33KB
- apdn-20240130_pre.xml (EX-101.PRE) — 22KB
- tm244443d1_8k_htm.xml (XML) — 3KB
02
Item 1.02 Termination of a Material Definitive Agreement. On November 7, 2023 , Applied DNA Sciences, Inc. (the "Company") entered into an Equity Distribution Agreement (the "Equity Distribution Agreement") with Maxim Group LLC, as sales agent (the "Agent"), pursuant to which the Company may, from time to time, issue and sell shares of its common stock, in an aggregate offering price of up to $ 6,397,939 through the Agent. Under the terms of the Equity Distribution Agreement, the Agent may sell the shares of common stock at ma rket prices by any method that is deemed to be an "at the market offering" as defined in Rule 415 under the Securities Act of 1933, as amended . 90,027 shares of common stock were sold pursuant to the Equity Distribution Agreement. Effective January 30, 2024, the Company terminated the Equity Distribution Agreement by providing a notice of termination to the Agent in accordance with the terms of the Equity Distribution Agreement. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly author ized. Date: January 30, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer